GoodRx and Viatris Partner to Slash Prices on 17 Brand Medications
Event summary
- GoodRx and Viatris have partnered to offer up to 85% savings on 17 established brand medications, including Lipitor, Celebrex, Viagra, and Norvasc.
- Eligible commercially insured patients can pay as low as $0–$4 on select Viatris medications through GoodRx.
- Cash-paying consumers can access discounted cash prices at over 70,000 pharmacies nationwide.
- The collaboration aims to make these medications more affordable and accessible, addressing cost barriers for patients.
- GoodRx's platform is used by nearly 25 million consumers and over one million healthcare professionals annually.
The big picture
This partnership underscores GoodRx's role as a trusted platform for operationalizing affordability strategies for pharmaceutical manufacturers. As pricing dynamics and consumer expectations continue to shift, such collaborations are becoming crucial for maintaining access to established brand medications. The deal highlights the growing trend of pharmaceutical companies leveraging third-party platforms to enhance medication affordability and patient adherence.
What we're watching
- Market Penetration
- How the partnership will affect GoodRx's ability to expand its user base and increase engagement with cash-paying consumers.
- Competitive Dynamics
- Whether this collaboration will prompt other pharmaceutical companies to seek similar partnerships with GoodRx to remain competitive.
- Regulatory Impact
- The pace at which regulatory bodies may scrutinize such partnerships, given their potential to influence medication pricing and access.
Related topics